GHRP-2
aka Growth Hormone Releasing Peptide-2
Mechanism
GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist that stimulates pituitary growth hormone release. It is approved in Japan (Kaken Pharmaceutical, 2004) as a single-dose diagnostic agent for GH deficiency, but is NOT FDA-approved in the US and is research-only. Unlike ipamorelin, GHRP-2 is non-selective and modestly raises ACTH, cortisol, and prolactin.
Identification
| CAS number | 158861-67-7 |
|---|---|
| Molecular formula | C45H55N9O6 |
| Sequence | AAWFK |
| Typical dose | 100–300 mcg per injection, 2–3x daily, subcutaneous |
| Half-life | ~15–30 minutes |
Vendors selling GHRP-2
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Moglabs | 5 mg | $16.00 | — | 96 |
| Ion Peptide | 5 mg | $29.00 | — | 95 |
| Peptide Tech | — | $18.99 | — | 94 |
| Peptidology | 10 mg | $42.99 | — | 89 |
| Qihang Peptide | — | — | — | 87 |
| Simple Peptide | — | $39.00 | — | 85 |
| Peptidegurus | 5 mg | — | — | 84 |
| Peptidegurus | 10 mg | — | — | 84 |
| Crystal Peptides | 5 mg | $24.96 | — | 66 |
| Certified Peptides | 10 mg | $46.00 | — | 62 |
| Peptiatlas | — | — | — | 51 |
| DongCheng Peptide | — | — | — | 46 |
| Mandy | 5 mg | $21.00 | — | 43 |
| HongDa Peptide | — | $29.00 | — | 43 |
| HongDa Peptide | — | $29.00 | — | 43 |
| zztai Peptide Ltd | — | — | — | 43 |
| MJT peptides | 5 mg | $24.00 | — | 39 |
| Alpha Omega | — | $39.00 | — | — |
| Atomik Labz | 10 mg | $39.00 | — | — |
| Biotech Peptides | 5 mg | $20.00 | — | — |
| Biotech Peptides | 10 mg | $39.00 | — | — |
| Core Peptides | 10 mg | $20.00 | — | — |
| Core Peptides | 5 mg | $20.00 | — | — |
| Genetic Peptide | 10 mg | $40.00 | — | — |
| Kimera Chems | — | $21.99 | — | — |
| Modern Research Peptides | 10 mg | $29.99 | — | — |
| Oasis Labs | 10 mg | $47.00 | — | — |
| Solution Peptides | 10 mg | $39.00 | — | — |
| Solution Peptides | 5 mg | $19.00 | — | — |
| Soma Peptides | 10 mg | $44.00 | — | — |
Research
Summary Rathke's cleft cyst (RCC) is a benign sellar or suprasellar lesion increasingly detected by magnetic resonance imaging (MRI).
source →Growth hormone-releasing peptides (GHRPs) comprise a group of small synthetic peptides that can effectively influence growth hormone secretion both in humans and animals.
source →Trans-sellar encephalocele (TSE) is a rare congenital anomaly of the cranial base characterized by herniation of intracranial contents through the sellar floor. Although clinical presentations are diverse, the prevalence and characteristics of endocrine dysfunction due to hypothalamic-pituitary involvement are unclear.
source →Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
source →Medulloblastoma, a common pediatric central nervous system disease, is managed with surgery, chemotherapy, and craniospinal irradiation (CSI) delivered with either X-rays or protons. Proton-beam CSI, introduced to protect the surrounding tissues, may reduce endocrine toxicity.
source →We encountered a patient with a body mass index of 50.7 kg/m 2 . Behavioral therapy was effective for preventing progression of health disturbance in this case. When coping with severe obesity, we must promote various tests to differentiate secondary obesity.
source →Dried blood spots (DBSs) sampling is gaining support by the antidoping community because of simplicity and cost-effective characteristics, especially in collection, transport, and storage. Nevertheless, DBS applicability demands specific studies for each of the analytes proposed for testing.
source →Growth hormone releasing peptides (GHRPs) are synthetic peptides with the ability to stimulate human growth hormone (hGH) secretion. Several GHRPs have been developed as drug candidates; however, only one of them, GHRP-2 (Pralmorelin), has received a clinical approval.
source →Because growth hormone (GH) secretion is reportedly decreased in obese patients, we examined not only the factors associated with the decreased GH secretion but also GH response to the GH-releasing peptide (GHRP)-2-load test before and after laparoscopic gastrectomy (LSG).
source →Unlabelled The objective of this study was to investigate the effects of growth hormone-releasing peptide-2 (GHRP-2) and cysteamine (CS) administration on growth performance in yaks with growth retardation and try to elucidate its regulatory mechanisms.
source →GHRP-2 is a synthetic agonist of ghrelin receptor. GHRP-2 has similar physiological functions with ghrelin. In our previous study, ghrelin (i.c.v.) could induce analgesic effect through an interaction with GHS-R1α and with the central opioid system in the acute pain in mice.
source →